Soligenix Enhances Vaccine Stability with ThermoVax® for Ebolavirus and Other Threats

Soligenix Advances ThermoVax® Technology for Vaccine Stability

In a significant development, Soligenix, Inc. announces promising results from its collaboration with Dr. Axel Lehrer at the University of Hawaiʻi at Mānoa regarding the stability of its ebolavirus vaccines. Utilizing the innovative ThermoVax® platform, the company demonstrates that both bivalent and trivalent vaccines retain their potency even after two years of storage at elevated temperatures of up to 40°C (104°F). These findings are integral in addressing public health concerns related to ebolavirus outbreaks, as they suggest that these vaccines can remain effective without the need for stringent cold-chain logistics, which are often a barrier in resource-limited settings.

The published study, titled "Thermostable Bivalent & Trivalent Filovirus Vaccines from Insect Cells: Potency Demonstrated after 3 Months and 2 Years," reveals that the vaccines not only maintain their potency over time but also elicit robust immune responses. In preclinical trials, the vaccines provide up to 100% protection in non-human primates, underscoring their potential efficacy in combating deadly viruses like Zaire ebolavirus and Sudan ebolavirus. Dr. Lehrer emphasizes the simplified logistics associated with the single-vial formulation, which facilitates ambient temperature shipping and easy reconstitution prior to application, enhancing the feasibility of broader vaccination campaigns.

Dr. Christopher J. Schaber, President and CEO of Soligenix, comments on the broader implications of the ThermoVax® platform, noting its successful application in stabilizing vaccines against various threats, including ricin toxin and COVID-19. He positions these protein subunit vaccines as a competitive gold standard due to their safety profile and reduced cold-storage requirements. This advancement not only aims to improve vaccination strategies but also enhances the preparedness for potential epidemics, particularly in areas where healthcare resources are scarce. The company's focus on developing stable, effective vaccines could play a pivotal role in global health initiatives aimed at preventing outbreaks.

In addition to the recent vaccine developments, Soligenix continues to advance its Specialized BioTherapeutics segment, with the photodynamic therapy HyBryte™ (SGX301) for cutaneous T-cell lymphoma showing promise as it heads toward regulatory approval. The company actively seeks to engage with stakeholders at the upcoming H.C. Wainwright 27th Annual Global Investment Conference, where they will provide updates on their ongoing projects and initiatives in rare disease treatment and public health solutions.

Soligenix's efforts to stabilize vaccine candidates through innovative technologies like ThermoVax® reflect a commitment to addressing urgent healthcare needs while enhancing global vaccination capabilities.